Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001493152-25-020081 0001832106 XXXXXXXX LIVE 2 Common Shares, no par value per share 02/03/2026 true 0001374339 74346M505 ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street Toronto A6 M4S 3E2 Fan Yu 852 31219699 c/o ABG Management Ltd. #3902, 39/F, E Tower, 10 Harcourt RD CTR Hong Kong K3 0000000000 0001832106 N ABG Management Ltd. WC N E9 0.00 572677.00 0.00 572677.00 572677.00 N 6.3 CO 0001822947 N Ally Bridge Group (NY) LLC WC N DE 0.00 572677.00 0.00 572677.00 572677.00 N 6.3 OO Limited Liability Company 0001831963 N Ally Bridge MedAlpha Master Fund L.P. WC N E9 0.00 572677.00 0.00 572677.00 572677.00 N 6.3 PN Y ABG V-SIV IX Limited WC N E9 0.00 659520.00 0.00 659520.00 659520.00 N 7.1 CO Y Ally Bridge Group Global Life Science Capital Partners V, L.P. WC N E9 0.00 659520.00 0.00 659520.00 659520.00 N 7.1 PN Y ABG Global Life Science Capital Partners V GP, L.P. WC N E9 0.00 659520.00 0.00 659520.00 659520.00 N 7.1 PN Y ABG Global Life Science Capital Partners V GP Limited WC N E9 0.00 659520.00 0.00 659520.00 659520.00 N 7.1 CO Y ABG V-SIV X Limited WC N E9 0.00 412200.00 0.00 412200.00 412200.00 N 4.5 CO 0001668029 N Fan Yu WC N O1 0.00 1644397.00 0.00 1644397.00 1644397.00 N 17.0 IN Common Shares, no par value per share ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street Toronto A6 M4S 3E2 Item 2 is amended and restated in its entirety by the following: The Schedule 13D is being filed by the following persons (each a "Reporting Person" and, collectively, the "Reporting Persons"): ABG Management Ltd. Ally Bridge Group (NY) LLC Ally Bridge MedAlpha Master Fund L.P. ABG V-SIV IX Limited Ally Bridge Group Global Life Science Capital Partners V, L.P. ABG Global Life Science Capital Partners V GP, L.P. ABG Global Life Science Capital Partners V GP Limited ABG V-SIV X Limited Mr. Fan Yu The principal business office address for Ally Bridge Group (NY) LLC and ABG V-SIV IX Limited is 430 Park Avenue, 12th Floor, New York, NY 10022. The principal business office address for ABG Management Ltd. and Mr. Fan Yu is Unit 3902, 39/F, East Tower Cheung Kong Center II, 10 Harcourt Road Central, Hong Kong. The principal business office address for the remaining Reporting Persons is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, Cayman Islands. The Reporting Persons are principally engaged in the business of investing in securities, including of the Issuer. During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, none of the Reporting Persons were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Ally Bridge Group (NY) LLC is organized under the laws of the State of Delaware. Mr. Fan Yu is a citizen of Malta. Each of the other Reporting Persons is organized under the laws of the Cayman Islands. Item 3 is amended and supplemented by the following: On February 3, 2026, in connection with the closing of the previously disclosed Offering pursuant to the Securities Purchase Agreement: (i) Ally Bridge MedAlpha Master Fund L.P. purchased an aggregate of 164,881 common shares, no par value per share (the "Common Shares") and warrants (the "Warrants") to purchase 164,881 Common Shares for aggregate consideration of $2,000,006.53; (ii) ABG V-SIV IX Limited purchased an aggregate of 329,760 Common Shares and Warrants to purchase 329,760 Common Shares for aggregate consideration of $3,999,988.80; and (iii) ABG V-SIV X Limited purchased an aggregate of 206,100 Common Shares and Warrants to purchase 206,100 Common Shares for aggregate consideration of $2,499,993 (together, the "Offering"). The Reporting Persons obtained the funds used to purchase the Common Shares and warrants through capital contributions from their partners. Item 4 is amended and supplemented by the following: CLOSING OF OFFERING On February 3, 2026, the previously disclosed Offering closed. REGISTRATION RIGHTS AGREEMENT On February 3, 2026, in connection with the closing of the Offering, the Issuer entered into a registration rights agreement (the "2026 Registration Rights Agreement") with the investors in the Offering, pursuant to which the Issuer is required to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of the Common Shares issued to the investors pursuant to the Securities Purchase Agreement, together with the Common Shares underlying the Warrants. The foregoing description of the 2026 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the form-of 2026 Registration Rights Agreement, which is attached as an exhibit to this Schedule 13D and incorporated herein by reference. REVERSE STOCK SPLIT The amount of Common Shares reported herein reflects a 1-for-25 reverse stock split that occurred on November 28, 2025. Item 5 is amended and restated in its entirety by the following: The information contained on the cover pages is incorporated by reference into this Item 5. The ownership information presented herein represents beneficial ownership of the Issuer's Common Shares, based on 8,967,693 Common Shares outstanding immediately following the closing of the Offering. The Common Shares reported as beneficially owned herein include: (i) 407,230 Common Shares and 164,881 Common Shares issuable upon the exercise of Warrants held of record by Ally Bridge MedAlpha Master Fund L.P., (ii) 329,760 Common Shares and 329,760 Common Shares issuable upon the exercise of Warrants held of record by ABG V-SIV IX Limited and (iii) 206,100 Common Shares and 206,100 Common Shares issuable upon the exercise of Warrants held of record by ABG V-SIV X Limited. Additionally, there are 566 Common Shares underlying an employee stock option granted to Dr. Alex by the Issuer and held by him for the benefit of Ally Bridge MedAlpha Master Fund L.P., which amount represents the number of Common Shares that are currently vested or that will vest within 60 days of the date of this filing. The amount of securities reported herein does not include 387,600 Common Shares issuable upon exercise of warrants held of record by Ally Bridge MedAlpha Master Fund L.P., which are subject to limitations on exercise. Mr. Fan Yu is the controlling stockholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by Ally Bridge MedAlpha Master Fund L.P. Mr. Fan Yu is also the indirect controlling stockholder of ABG Global Life Science Capital Partners V GP Limited, which is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of Ally Bridge Group Global Life Science Capital Partners V, L.P., which is the controlling shareholder of ABG V-SIV IX Limited. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV IX Limited. Mr. Fan Yu is also the controlling stockholder of ABG V-SIV X Limited. As such, Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV X Limited. The information contained on the cover pages is incorporated by reference into this Item 5. Except as described in this Schedule 13D, the Reporting Persons have not effected any transactions in the Common Shares during the past sixty days. None. Not applicable. Item 6 is amended and supplemented by the following. Item 4 above summarizes certain provisions of the 2026 Registration Rights Agreement and is incorporated herein by reference. A copy of such agreement is attached as an exhibit to this Schedule 13D and is incorporated herein by reference. Except as set forth herein, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies. Item 7 is amended and restated in its entirety by the following: Exhibit 1: Joint Filing Agreement (Previously Filed). Exhibit 2: Registration Rights Agreement, dated as of August 21, 2023 (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on August 22, 2023). Exhibit 3: Registration Rights Agreement, dated as of July 26, 2024 (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on July 26, 2024). Exhibit 4: Registration Rights Agreement, dated as of July 28, 2025 (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on July 28, 2025). Exhibit 5: Form of Securities Purchase Agreement, dated as of January 29, 2026 (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the SEC on January 30, 2026). Exhibit 6: Form of Registration Rights Agreement, dated as of February 3, 2026, (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on January 30, 2026). Exhibit 7: February 2026 Joint Filing Agreement. ABG Management Ltd. By: /s/ Fan Yu Fan Yu, Director 02/05/2026 Ally Bridge Group (NY) LLC By: ABG Management Ltd., its managing member, By: /s/ Fan Yu Fan Yu, Director 02/05/2026 Ally Bridge MedAlpha Master Fund L.P. By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu Fan Yu, Director 02/05/2026 ABG V-SIV IX Limited By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Fan Yu Fan Yu, Director 02/05/2026 Ally Bridge Group Global Life Science Capital Partners V, L.P. By: ABG Global Life Science Capital Partners V GP, L.P., its GP, By: ABG Global Life Science Capital Partners V GP Limited, its GP, By: /s/ Fan Yu Fan Yu, Director 02/05/2026 ABG Global Life Science Capital Partners V GP, L.P. By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Fan Yu Fan Yu, Director 02/05/2026 ABG Global Life Science Capital Partners V GP Limited By: /s/ Fan Yu Fan Yu, Director 02/05/2026 ABG V-SIV X Limited By: /s/ Fan Yu Fan Yu, Director 02/05/2026 Fan Yu /s/ Fan Yu Fan Yu 02/05/2026